ABSTRACT
INTRODUCTION
Invasive breast carcinoma is the most common cancer in women, and despite major advances in screening and treatment, it remains the second leading cause of death from cancer.
Breast tumors are extremely heterogeneous, with no dominant pathway or histological subtype prevailing, and thus there is no standardized treatment applicable to all types (1) .
Characterization of breast cancer has historically been done on the basis of histological traits and size or spread of the tumor, along with various pathological markers such as estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) (2) . Expression of the epidermal growth factor receptor (EGFR) has been linked to the basallike subtype, with overexpression in >50% of tumors (5) . While EGFR amplification is generally rare in breast cancer, basal-like tumors have a relatively high incidence of EGFR amplification (6) . Variants of the EGFR are common across tumors, with one of the most prevalent being EGFR variant III (EGFRvIII). EGFRvIII is a naturally occurring constitutively active variant that was originally identified in a high percentage of glioblastoma multiforme (GBM) brain tumors. It is found in 15-60% of primary GBM, and is mostly associated with amplification and rearrangement at the EGFR locus (7) . The rearranged EGFR gene deletes exons 2 through 7 resulting in an in-frame 801 base pair deletion. This gives rise to a truncated receptor lacking a significant portion of the extracellular ligand-binding domain, rendering EGFRvIII ligandindependent and constitutively active (8) .
EGFRvIII expression in other tumor types has been documented, but remains controversial (9) (10) (11) (12) (13) . Previous reports demonstrated EGFRvIII expression in breast carcinoma by western blotting and RT-PCR (9, 12) , but subsequent studies have provided conflicting evidence depending on the method of detection (14, 15) . However, EGFRvIII is posited to be involved in tumorigenicity, invasiveness and metastasis in breast cancer (16) (17) (18) (19) . In this study we investigated the expression of EGFRvIII and the presence of EGFR amplification and rearrangement in primary breast carcinomas, and generated inducible EGFRvIII-expressing cell lines to elucidate novel roles for EGFRvIII in tumorigenesis.
MATERIALS AND METHODS

Dissociation of primary human breast tumors.
Freshly resected human breast tumor samples, tumor-adjacent normal tissue samples, corresponding metastatic lymph nodes, and non-tumor associated normal breast samples were obtained from the Stanford University tissue bank under IRB approved protocols. Tissue samples were dissociated using 1x Collagenase/Hyaluronidase (Stem Cell Technologies) and treated with ACK/RBC lysis buffer (0.15M NH 4 Cl, 1.0mM KHCO 3 and 0.1mM Na 2 -EDTA). Resulting cells were either resuspended in sterile FACS buffer for flow cytometry or used for RNA isolation.
Nested RT-PCR. RNA from primary human breast tumors was utilized for nested RT-PCR using a method adapted from Ge et al. (20) . Reaction products were electrophoresed in 2% agarose gels. Products were excised and purified using Qiagen's gel extraction kit and sequencing was carried out by Elim BioPharm.
Flow cytometry.
Prior to flow cytometry analysis or sorting, cells were dissociated as above or washed and dissociated using TrypLE (Gibco). Cells were resuspended in a 100μl staining volume of FACS buffer (HBSS + 0.1% BSA) and kept on ice. The following antibodies were used in flow cytometry: monoclonal mouse anti-EGFRvIII antibody (G100, Zymed), CD44-APC (BD Biosciences), CD24-FITC or CD24-PE (BD Biosciences), CD31-PeCy7 (eBioscience), and CD45-PeCy7 (BD Biosciences). Detection of aldehyde dehydrogenase (ALDH) activity was performed using the Aldefluor assay (Stem Cell Technologies) according to the manufacturer instructions. DAPI was used to discriminate between live and dead cells. CD31 and CD45
antibodies were utilized for lineage depletion. All analyses were conducted on live, lineage-negative cells. Samples were analyzed on a LSR II FACS machine (BD Biosciences) or sorted on an ARIA-II (BD Biosciences) at the Stanford University FACS facility. Appropriate isotype controls were used to control for non-specific isotype background. To validate the significance of the observed differences we analyzed variables using two-sided t tests.
Immunohistochemistry (IHC).
Unstained sections from formalin-fixed paraffin-embedded samples of invasive breast carcinoma were acquired from the pathology division of Stanford Medical Center with all patient identification removed. Additionally, a tissue microarray was obtained containing 60 cases of invasive breast carcinoma (US Biomax, Cat# BR1503a). Slides were deparaffinized in xylene and then rehydrated with ethanol and double distilled water (ddH20). Hydrogen peroxide was used to block non-specific sites and Diva Decloaker (BioCare Medical) solution and microwaving were used for antigen retrieval. Sections were incubated overnight with a 1 ȝg/ml solution of an anti-EGFRvIII antibody (G100, Zymed), that recognizes EGFRvIII but does not cross-react with wtEGFR. Expression was detected using HRP antimouse secondary antibody (BioCare Medical) and betazoid DAB (BioCare Medical). The slides were counterstained with hematoxylin. To compare EGFRvIII expression and ER/PR/HER2 phenotype, we used the Ȥ2 and Fisher exact tests.
Quantitative RT-PCR (qRT-PCR).
RNA was isolated from adherent cell cultures using Trizol reagent according to the manufacturer's instructions (Invitrogen) or from sorted cells using the RNeasy Micro Kit (Qiagen). Complementary DNA synthesis and quantitative PCR were carried out with the Power SYBR Green RNA-to-CT 1-Step Kit (Applied Biosystems). Primer sequences are listed in Supplemental Table 3 . PCR conditions were 48°C for 30 min, 95°C for 8 published protocol (22) . Briefly, three primer sets were employed, two within the EGFR gene and a third internal control (ȕ-actin). Of the two EGFR primers, one is within the EGFRvIII deleted region (Exon 2) and the other is external to the EGFRvIII deleted region (Intron 15).
Each reaction was performed in triplicate in 384-well optical plates on an ABI 7900HT instrument (Applied Biosystems). Relative copy number was determined using the comparative Ct method. U87 served as the normal control DNA.
Microarray analysis. High resolution array comparative genomic hybridization (aCGH) data characterizing copy number across 169 primary breast samples were acquired from two previous studies (23, 24) . High resolution aCGH data across 54 breast cancer cell lines was obtained from the Wellcome Trust Sanger Institute Cancer Genome Project. Lastly, aCGH data from select EGFRvIII positive samples were curated from The Cancer Genome Atlas (TCGA) public archives (25) . These studies were performed on three different array platforms: Affy SNP 5.0 (23) , Affy SNP6.0 Sanger, TCGA , and Agilent 244K (24) . Probes from the more dense Affy SNP arrays were collapsed to their nearest neighbor on the Agilent 244K array in order to enable visualization on the same heatmap.
Cell lines and expression plasmids utilized. Parental SUM149 and SUM159 cell lines were a kind gift of Dr. Jonathan Pollack and cultured as previously described (26) . Parental MCF10A
and U87-MG cells were obtained and cultured according to ATCC protocols. U87-MG cells expressing EGFRvIII (U87-vIII) were a kind gift of Dr. Donald O'Rourke and were maintained in geneticin selection at 500 ȝg/mL. EGFRvIII-inducible cell lines were created using the TetOff Advanced system (Clontech), according to manufacturer's instructions and maintained in 9 puromycin (2 ȝg/mL) and geneticin (500 ȝg/mL) selection. EGFRvIII gene expression was regulated by the addition or withdrawal of 100 ng/ul doxycyline.
Western blot. Cells were lysed with cold PBS/TDS buffer (PBS with 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 1 mmol/L EDTA, 1 mmol/L phenylmethylsulfonyl fluoride, complete inhibitor cocktail; Roche Applied Science). The signal was detected using the ECL system (Amersham Biosciences). The following antibodies were used for immunoblotting: G100,
Biotechnology, Inc.), N-Cadherin (Santa Cruz Biotechnology, Inc.), ALDH (BD Biosciences), Slug (Santa Cruz Biotechnology, Inc.) and active β-catenin (ABC, Millipore).
Sphere formation. Single cells were plated in ultra-low attachment plates (Corning) at limiting dilutions or at a density of 3,000 cells per well. Cells were cultured in Mammocult media according to the manufacturer's instructions (Stem Cell Technologies). For estimation of sphere initiating cell frequency, limiting dilution analysis (LDA) was done as described previously (27, 28) . Cultures were carried out for 7 days and scored for wells which did not have spheres. An extreme LDA algorithm was used to determine the frequency of sphere initiating cells (29) . Each experiment was done in triplicate and analyzed using two-sided t tests. 
RESULTS
EGFRvIII is expressed in primary breast carcinoma using multiple methods of detection
To assay for the presence of EGFRvIII in primary breast carcinoma, we first analyzed EGFRvIII expression using immunohistochemical (IHC) analysis with an antibody specific for EGFRvIII. IHC revealed that 5% (7/136) of cases were EGFRvIII positive. Some displayed lowlevel expression in the majority of tumor epithelial cells, while others had more focal staining patterns ( Figure 1A) . One case showed positivity in only a single duct, suggesting that EGFRvIII expression may be extremely rare and sporadic in some tumors ( Figure 1A , Sample BR89). To confirm EGFRvIII expression, we performed nested RT-PCR and sequencing analysis of RNA isolated from these tumors. The resulting PCR product validated EGFRvIII expression ( Figure   1B ) and the band was confirmed as an EGFRvIII product by sequencing ( Figure 1C Utilizing data from 147 cases analyzed by IHC or flow cytometry and RT-PCR, we found 9 of 13 (69%) EGFRvIII-positive tumors were of the ER+/PR+/HER2-subset, while only 3 of 13 (23%) were ER-/PR-/HER2-and 1 of 13 (8%) was ER+/PR-/HER2-(Supplemental Table 1 ).
EGFRvIII expression was significantly associated with the ER+/PR+/HER2-subtype (p<0.01), but there was no significant association of EGFRvIII positivity with triple-negative breast cancer or the other subtypes.
We also observed the presence of EGFRvIII-positive cells in some samples of normallike breast tissue adjacent to the primary tumor and in metastatic tumors of the lymph node using flow cytometry and nested RT-PCR analyses (Supplemental Table 2 ). In general the percentage of EGFRvIII-positive cells was lower in the adjacent normal tissue compared to the primary tumor, but higher in the metastatic tissue. Additionally, we did not observe EGFRvIII expression in 6 samples from non-tumor associated normal breast tissues (NTB), implying that EGFRvIII is not expressed in normal non-cancerous breast cells (Supplemental Figure 1) . While this is a small sample size, the data suggests that EGFRvIII-positive cells may be present in what is thought to be extra-tumoral "normal" tissue and also in metastatic sites.
EGFRvIII-expressing breast tumors do not show rearrangement or amplification of the
EGFR locus
EGFR locus amplification and rearrangement are common in GBM, but rare in other tumor types. EGFRvIII was originally identified as a genomic rearrangement, but it has been postulated that other mechanisms, such as alternative splicing, could also give rise to the variant (9) . Additionally, the above analyses demonstrated that EGFRvIII is often expressed at a very low level compared to what we observe in GBM. We screened the tumors deemed EGFRvIIIpositive by IHC for EGFR amplification and rearrangement using several methods. Long-range PCR was performed to attempt to amplify a fragment corresponding to rearranged EGFR This method was readily able to identify rearranged DNA corresponding to EGFRvIII in a control primary GBM case, but no rearrangement existed in the primary breast carcinoma samples ( Figure 2A ). FISH was performed using an EGFR specific probe to assess amplification, which showed normal copy number of EGFR and chromosome 7 in tumors with expression of EGFRvIII protein ( Figure 2B ). Lastly, qPCR was conducted to verify that no amplification and rearrangement occurred using a method adapted from Biernat et al. (22) . This qPCR method employs two primer sets to calculate DNA copy number, one within the EGFRvIII deleted region (Exon 2), and the other external to the EGFRvIII deleted region (Intron 15), with normalization to an internal control primer set (ȕ-actin) and a control cell line containing a normal copy number of EGFR and chromosome 7. This method readily detected EGFR amplification and rearrangement in a control GBM cell line, while the primary breast carcinoma samples had no amplification or rearrangement of the EGFR locus ( Figure 2C ). Because our sample size was limited, we also looked for evidence of EGFR rearrangement corresponding to EGFRvIII in more than 200 primary breast and breast cancer cell line samples using array comparative genomic hybridization (arrayCGH). The EGFRvIII rearrangement was not observed in any of these cases, even though EGFRvIII was readily detected in GBM samples ( Figure 2D ). This demonstrates that although EGFRvIII is expressed in primary breast carcinoma, it does not originate through amplification and rearrangement of the EGFR locus. 
EGFRvIII correlates with stem-cell associated marker and gene expression
Evidence from other tumor types demonstrates that EGFRvIII can contribute to chemotherapy and radiation resistance, suggesting that EGFRvIII may play a role in a critical population of cells required for tumorigenesis or tumor progression (30, 31 and expression in EGFRvIII-expressing cell lines compared to the control cells ( Figure 4G ). 
EGFRvIII contributes to enhanced in vitro sphere and in vivo tumor formation
Neurosphere culture has become widely accepted as a method for culturing cells capable of self-renewal and tumor initiation from primary GBM and has since been adapted for other tumor types (36) . We analyzed in vitro sphere formation in breast carcinoma cells utilizing the 
EGFRvIII mediates its effects through activation of Wnt signaling
To begin to understand the mechanism by which EGFRvIII induces CSC-associated gene expression changes and upregulation of putative breast CSC markers, we assessed activation of the Wnt pathway, which is one of several signaling pathways thought to play a role in mammary stem cell phenotypes (37) (38) (39) . When this pathway becomes activated β-catenin will become stabilized, translocate to the nucleus, and interact with and activate the transcription factor TCF/LEF-1. Both SUM159-EGFRvIII and MCF10A-EGFRvIII cell lines displayed a 2 to 4-fold increase in activated β-catenin (ABC) expression ( Figure 4F ). Additionally, we determined whether this increase was functionally significant by utilizing the pTopFLASH-GFP reporter system. This system places three copies of the TCF-response motif upstream of a minimal c-fos 
DISCUSSION
Our results demonstrate that EGFRvIII is expressed in primary breast carcinoma and contributes to CSC phenotypes in EGFRvIII-expressing cell lines. This agrees with previous studies reporting EGFRvIII expression in breast cancer (9, 12, 20) . However, several studies have been unable to verify this expression (14, 15) . In general, there is no consistently used EGFRvIII-specific antibody or detection assay, which could lead to varying sensitivities and specificities. We also noted a discrepancy between our IHC and flow cytometry/RT-PCR analyses. We believe this is likely due to a high false-negative rate in IHC analysis and the actual incidence is closer to that predicted by both flow cytometry and RT-PCR (69%). A potential explanation for the high false-negative rate in IHC analysis may be sampling bias, as our results suggest that EGFRvIII may be expressed focally and sporadically in some tumors. In cases with such low expression it is probable that a given section, especially if it is small in size, might not contain EGFRvIII positive cells. Indeed, anecdotally we have found that in tumors with low percentages of positive cells, some sections will contain positive cells and others will not.
Studies that have been able to successfully identify EGFRvIII in a high percentage of cases utilized a nested RT-PCR approach and/or microdissection of positive regions of the tumor prior to RT-PCR (15, 20) . We also could only readily identify EGFRvIII in a high percentage of cases using a nested RT-PCR approach and additionally on a cell-by cell basis using flow cytometry.
Nested RT-PCR can carry the risk of false-positives; however, using flow cytometry we identified EGFRvIII mRNA in only EGFRvIII-positive, but not negative, sorted fractions, and we also confirmed the EGFRvIII junction utilizing sequencing, indicating that our protocol has expression in breast cancer as compared to what is observed in GBM and lack of amplification or rearrangement of the EGFR locus. This suggests that another mechanism, such as alternative splicing, may account for its presence and the difficulty in detection compared to GBM.
We also observed a correlation between EGFRvIII expression and the ER+/PR+/HER2-subtype. These tumors are thought to fall within the Luminal A category, whereas wtEGFR expression and amplification is usually associated with triple-negative/basal breast cancer (3, 5) .
Given the lack of amplification we observed in EGFRvIII-expressing tumors, it is perhaps not surprising that EGFRvIII expression would correlate with a different tumor subtype. It is also likely that EGFRvIII signaling would be most advantageous in a tumor type without redundancy from other ErbB family members, suggesting a potentially novel role for this oncogene in tumors typically lacking wtEGFR or HER2 expression.
While EGFRvIII is rarely found in normal non-cancerous tissue (9), we were surprised to Furthermore, since EGFRvIII has been implicated in chemo-and radiation-therapy resistance (30, 31) , these residual cells may be cause for particular concern. Currently an EGFRvIIIspecific peptide vaccine directed against the unique epitope present at the exon1-8 junction is indicates statistically significance differences (*= P<0.05. **= P<0.01, ***=P<0.001). 
